NeuroTrauma Sciences
NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neurosteroid prodrug therapeutics, led by NTS-104 for acute ischemic stroke, chronic stroke, and traumatic brain injury. The company was founded in 2016 and is completing Phase 1 trials.
- Company typePrivate
- Founded2016
- HeadquartersAlpharetta, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NeuroTrauma Sciences does
NeuroTrauma Sciences (NTS) is a privately held, clinical-stage biopharmaceutical company founded in 2016 and headquartered in Alpharetta, Georgia. The company is developing neuroprotective therapeutics for acquired brain injury, with a primary focus on acute ischemic stroke (AIS), and secondary indications in chronic stroke and traumatic brain injury (TBI). NTS targets therapeutic areas where there are no FDA-approved neuroprotective drugs and where more than 100 prior stroke neuroprotection trials have failed, framing its differentiated mechanism as a deliberate response to that clinical attrition. The firm currently has 11-50 employees and is pre-revenue.
NTS's core technology is a neurosteroid prodrug platform licensed exclusively worldwide from Emory University. The lead asset, NTS-104, is a water-soluble prodrug that converts rapidly in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and engages three receptor targets — full antagonism at the androgen receptor, partial agonism at cellular progesterone receptor B, and full antagonism at the mineralocorticoid receptor. This multi-targeted mechanism produces anti-inflammatory, anti-apoptotic, and anti-edema activity in brain and systemic tissue, with dose-dependent improvements in neurological severity scores, motor function, and infarct size in preclinical eMCAO stroke models. A next-generation candidate designed for subcutaneous or intramuscular administration extends the pipeline beyond intravenous delivery. NTS-104 entered first-in-human dosing in a US Phase 1 study in June 2023 (NCT05547438), with Phase 1 completion planned for 2025 and Phase 2 development in acute ischemic stroke as the next step. The product portfolio is supported by collaborations with Antwerp University Hospital (CENTER-TBI) and research relationships with Emory, University of Miami, Columbia University, and Henry Ford Health.
The company's business model is pre-commercial. NTS is not yet generating revenue and will not do so until regulatory approval and market launch of NTS-104 or pipeline successors, at which point revenue will derive from pharmaceutical product sales to hospitals and healthcare systems via enterprise pharmaceutical distribution channels. Pricing has not been disclosed and will be set post-approval. The company monetizes its current asset base through scientific publication, conference presence (ISC, BIO, NNS), and academic-industry research partnerships rather than product sales. Capital formation to date has been via private funding rounds, with specific amounts, lead investors, and valuation not publicly disclosed. The Emory license carries milestone payments and a single-digit royalty obligation on future sales.
NeuroTrauma Sciences firmographics
Firmographics- Name
- NeuroTrauma Sciences
- Legal name
- NeuroTrauma Sciences, LLC
- Website
- https://neurotraumasciences.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neurosteroid prodrug therapeutics, led by NTS-104 for acute ischemic stroke, chronic stroke, and traumatic brain injury. The company was founded in 2016 and is completing Phase 1 trials.
- Ownership category
- akta.pro rank
NeuroTrauma Sciences industry classification
Industry- Product category
- Neuroprotective Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Stroke & Vascular Neurology (HLAKAIAG), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where NeuroTrauma Sciences is headquartered
LocationHeadquarters
- HQ city
- Alpharetta
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NeuroTrauma Sciences business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage biopharmaceutical company. Revenue will be generated through sales of NTS-104 and pipeline compounds upon FDA approval for acute ischemic stroke, chronic stroke, and potentially traumatic brain injury.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NeuroTrauma Sciences product offering
Product offeringCore offering
NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neuroprotective therapeutics for acquired brain injury. Its lead candidate NTS-104 is a water-soluble neurosteroid prodrug administered intravenously that converts in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and provides anti-inflammatory, anti-apoptotic, and anti-edema activity. The pipeline targets acute ischemic stroke, chronic stroke, and traumatic brain injury.
Product overview
NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing a pipeline of neuroprotective therapeutics for stroke and traumatic brain injury. The core product is NTS-104, a water-soluble intravenous neurosteroid prodrug that converts to the active metabolite NTS-105. The pipeline includes a next-generation candidate for subcutaneous/intramuscular administration. The company was founded in 2016 and completed Phase 1 clinical trials with NTS-104 in 2025.
Differentiator
Problem solved
Functional benefit
Products and services
- NTS-104 Water-soluble neurosteroid prodrug administered intravenously that converts rapidly in plasma to the active metabolite NTS-105. Being developed for acute ischemic stroke and chronic stroke with multi-targeted mechanisms including anti-inflammatory, anti-apoptotic, and anti-edema activity.
- Next-Generation Neurosteroid Candidate
Quantifiable outcome
- NTS-104 markedly improved modified neurological severity score (mNSS) in a dose-dependent manner in preclinical eMCAO stroke model
- +2 more outcomes
Companies that use NeuroTrauma Sciences
Customer profileSegments3 records
Ideal customer profiles2 records
NeuroTrauma Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
NeuroTrauma Sciences partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and minor.
- Antwerp University Hospital, BelgiumcoreNeuroTrauma Sciences entered into a research collaboration with Antwerp University Hospital to support CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI). The collaboration helps fund the continuation of this prospective longitudinal observational study collecting clinical and epidemiological data to identify most effective clinical care and treatment recommendations, validate surrogate biomarkers, and improve classification of TBI. NTS's funding ensures the CENTER-TBI network and infrastructure built over 7+ years will remain intact.
- Emory UniversitycoreNeuroTrauma Sciences entered into an exclusive worldwide license agreement with Emory University for patents and technology invented at Emory, including NTS-1104 and related compounds. Emory granted NTS exclusive worldwide license for proprietary neuroactive compounds for treatment of acquired brain injury such as ischemic stroke and traumatic brain injury, including concussion. NTS paid an undisclosed license fee and certain expenses to Emory, and Emory will receive milestone payments and a single-digit royalty on future sales.
- University of MiamiminorResearch partner identified on NeuroTrauma Sciences Connect page, collaborating on neuroscience research initiatives.
- Emory UniversitycoreResearch partner collaborating on neuroscience and drug development research as shown in partnership logos.
- Columbia UniversityminorResearch partner, particularly involving Barclay Morrison III, Ph.D. from Columbia University's Department of Biomedical Engineering who led research on NTS-105 in preclinical TBI models.
- Henry Ford HealthminorResearch partner collaborating on neuroscience and brain injury research initiatives.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
NeuroTrauma Sciences competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
NeuroTrauma Sciences social profiles
Digital presenceNeuroTrauma Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
NeuroTrauma Sciences leadership team
Management profileNumber of profiles
Profiles7 records
NeuroTrauma Sciences funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NeuroTrauma Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NeuroTrauma Sciences
What does NeuroTrauma Sciences do?
NeuroTrauma Sciences is a clinical-stage biopharmaceutical company developing neuroprotective therapeutics for acquired brain injury. Its lead candidate NTS-104 is a water-soluble neurosteroid prodrug administered intravenously that converts in plasma to the active metabolite NTS-105, which crosses the blood-brain barrier and provides anti-inflammatory, anti-apoptotic, and anti-edema activity. The pipeline targets acute ischemic stroke, chronic stroke, and traumatic brain injury.
Is NeuroTrauma Sciences a public or private company?
NeuroTrauma Sciences is a private company. It is classified as unknown and is currently operating.
When was NeuroTrauma Sciences founded?
NeuroTrauma Sciences was founded in 2016. It employs 11 to 50 people.
Where is NeuroTrauma Sciences based?
NeuroTrauma Sciences is headquartered in Alpharetta, United States, in the North America region.
How does NeuroTrauma Sciences make money?
One revenue line is on record: pharmaceutical Product Sales.
Does NeuroTrauma Sciences have an API?
No public API is recorded for NeuroTrauma Sciences.
What industry is NeuroTrauma Sciences in?
NeuroTrauma Sciences's product category is Neuroprotective Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAKAIAG, Stroke & Vascular Neurology. Its NAICS code is 541714 and its SIC code is 2833.